The full IgG199mTc-Cetuximab led to a significantly lower tumour to blood ratio compared to nanobody 99mTc-D10, despite a more than 10 fold higher affinity towards EGFR (0.5 nM)26. The gene discussed is CHRFAM7A; the disease is neoplasm.